1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Sanofi’s HERCULES Data In MS May Offer Path To Approval For Tolebrutinib

 
• By Joseph Haas

Delaying disease progression in non-relapsing secondary multiple sclerosis may get the BTK inhibitor approved, despite previous pivotal trial failures in relapsing MS.

Man with Multiple Sclerosis standing in his accessible kitchen with a cane
Sanofi's drug may address progressing disability related to MS • Source: Alamy

Sanofi likely bolstered the chances of its multiple sclerosis candidate tolebrutinib finding a treatment niche on 20 September as it reported data from the Phase III HERCULES study showing that the BTK inhibitor can delay disability progression in non-relapsing secondary progressive MS (nrSPMS) while demonstrating what one analyst called a manageable liver safety profile.

Key Takeaways

  • Sanofi’s BTK inhibitor tolebrutinib may offer a delay in confirmed disability in a subset of MS patients, new data from a Phase III study shows.

The data, presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference in Copenhagen, came roughly...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

Pipeline Watch: Eight Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D

Pipeline Watch: Eight Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.